Background: ALT-P1 (CJ-40002) is a long-acting recombinant growth hormone (GH) fused with NexP, which is a long-acting carrier developed by Alteogen Inc. NexP is a protein engineered recombinant alpha
Health Canada approved a phase I trial for Alteogen’s ALT02, a biosimilar version of trastuzumab
A novel ADC targeting HER2 pathways based on Alteogen's NexMab ADC technology.
 1  2  3  4